Hikma Pharmaceuticals PLC

Equities

HIK

GB00B0LCW083

Pharmaceuticals

Market Closed - London S.E. 11:35:26 2024-02-27 am EST 5-day change 1st Jan Change
1,990 GBX -0.18% Intraday chart for Hikma Pharmaceuticals PLC +0.15% +11.26%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Merck's Bridion faces generic threat from drugmaker Hikma RE
Barclays raises Breedon but cuts Domino's Pizza AN
FTSE 100 Closes Up After Nvidia Results Lead to Global Rally DJ
HIKMA PHARMACEUTICALS : Strong Generics-led finish to 2023 Alphavalue
JPMorgan Keeps Hikma Pharmaceuticals at Overweight, Raises PT MT
Transcript : Hikma Pharmaceuticals PLC, 2023 Earnings Call, Feb 22, 2024
Berenberg raises Moneysupermarket.com to 'buy' AN
Hikma boosts dividend after year of "significant progress" AN
Drugmaker Hikma expects profit to be slightly lower in 2024 RE
Hikma Pharmaceuticals Reports Improved FY23 Profit, Revenue MT
Earnings Flash (HIK.L) HIKMA PHARMACEUTICALS Posts FY23 EPS $0.85 MT
Hikma Pharmaceuticals PLC Provides Group Earnings Guidance for the Year 2024 CI
Hikma Pharmaceuticals PLC Announces Board Changes CI
Hikma Pharmaceuticals PLC Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Stocks to rise as Nvidia drives AI optimism AN
EMEA Morning Briefing : Stocks May Rise; Focus on PMI Data, Earnings DJ
Transcript : Hikma Pharmaceuticals PLC, 2023 Pre Recorded Earnings Call, Feb 22, 2024
FTSE 100 takes hit ahead of FOMC minutes AN
New Zealand Shares Rebound on Friday Close; AFT Pharmaceuticals Raises Operation Profit Guidance MT
AFT Pharmaceuticals Boosts Operating Profit Guidance for Fiscal Year 2024 MT
High-dose opioid reversal spray no better than lower dose in field, US study finds RE
AFT Pharmaceuticals' Licensee Launches Pain Relief Medication in US; Shares Rise 4% MT
AFT Pharmaceuticals’ Maxigesic IV Launches in the US MT
Hikma Announces US Launch of COMBOGESIC IV CI
UK’s FTSE 100 Index Closes Little Changed as US Jobs Soar MT
Chart Hikma Pharmaceuticals PLC
More charts
Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows: - generic injectable products (45.3%); - brand name drugs (27.5%); - generic products taken orally (26.7%); - other (0.5%). Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
25.26 USD
Average target price
28.37 USD
Spread / Average Target
+12.33%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Hikma Pharmaceuticals PLC - London S.E.
  4. News Hikma Pharmaceuticals PLC
  5. Arecor Therapeutics, Hikma Receive Positive Feedback for AT307 from US FDA
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW